期刊文献+
共找到67篇文章
< 1 2 4 >
每页显示 20 50 100
Structure based release kinetics analysis of doxazosin mesylate sustained-release tablets using micro-computed tomography
1
作者 Qian Liu Mengqing Zan +8 位作者 Hanhan Huang Hai Su Wenjing Zhang Lingyun Ma Guangchao Zhang Zunjian Zhang Jiwen Zhang Jianzhao Niu Mingdi Xu 《Asian Journal of Pharmaceutical Sciences》 SCIE CAS 2024年第6期154-162,共9页
The structures of solid dosage forms determine their release behaviors and are critical attributes for the design and evaluation of the solid dosage forms.Here,the 3D structures of doxazosin mesylate sustained-release... The structures of solid dosage forms determine their release behaviors and are critical attributes for the design and evaluation of the solid dosage forms.Here,the 3D structures of doxazosin mesylate sustained-release tablets were parallelly assessed by micro-computed tomography(micro-CT).There were no significant differences observed in the release profiles between the RLD and the generic formulation in the conventional dissolution,but the generic preparation released slightly faster in media with ethanol during an alcohol-induced dose-dumping test.With their 3D structures obtained via micro-CT determination,the unique release behaviors of both RLD and the generic were investigated to reveal the effects of internal fine structure on the release kinetics.The structural parameters for both preparations were similar in conventional dissolution test,while the dissolutions in ethanol media showed some distinctions between RLD and generic preparations due to their static and dynamic structures.Furthermore,the findings revealed that the presence of ethanol accelerated dissolution and induced changes in internal structure of both RLD and generic preparations.Moreover,structure parameters like volume and area of outer contour,remaining solid volume and cavity volumewere not equivalent between the two formulations in 40%ethanol.In conclusion,the structure data obtained from this study provided valuable insights into the diverse release behaviors observed in various modified-release formulations in drug development and quality control. 展开更多
关键词 Doxazosin mesylate sustained-release tablets Osmotic pump tablets Micro-computed tomography Three-dimensional structures ETHANOL
下载PDF
Pharmacokinetics of nifedipine sustained-release tablets in healthy Chinese volunteers 被引量:3
2
作者 武静 王本杰 +2 位作者 魏春敏 卜凡龙 郭瑞臣 《Journal of Chinese Pharmaceutical Sciences》 CAS 2007年第3期192-196,共5页
Aim To establish a LC-MS method for determining the concentration of nifedipine in human plasma and to evaluate the pharmacokinetic characteristics of nifedipine sustained-release tablets. Methods A XB-C18 (5 μm, 4.... Aim To establish a LC-MS method for determining the concentration of nifedipine in human plasma and to evaluate the pharmacokinetic characteristics of nifedipine sustained-release tablets. Methods A XB-C18 (5 μm, 4.6 mm ×150 mm) column and a mobile phase of methanol: 0.01 mol·L^-1ammonium acetate (60:40, V/V) were used to separate nifedipine, the detections was accuracy under atmosperic pressure electronic spray ionization (AP-ESI) mode and ion mass spectrum (m/z) of 314.9 [M+H]^+ for nifedipine, and 320.8 [M+H]^+ for lorazepam (Internal Standard, IS). Results The linear range of nifedipine was 0.3 - 80 ng·mL^-1 ( r = 0.9997), and the limit of quantitation (LOQ) was 0.3 ng·mL^-1. The nifedipine pharmacokinetic parameters after a single dose of 20 mg nifedipine sustained-release tablets test (T) or reference (R) were as the followings, t1/2 (6.73 ± 2.00) h and (7.04 ± 2.18) h, Tmax (4.28 ± 0.70) h and (4.48 ± 0.70) h, Cmax(39.66 ± 10.58) ng·mL^-1 and (40.19 ± 10.97) ng·mL^-1, AUC0-36 (391.63 ± 108.55) ng·mL^-1·h and (387.57 ± 121.51) ng·mL^-1·h, and AUC0-∞ (408.28 ± 121.16) ng·mL^-1·h and (406.15 ± 133.13) ng·mL^-1·h. The relative bioavailability of nifedipine sustained-release tablets (test) was (103.02 ± 13.93) %. Conclusion LC-MS method for the determination of concentrations of nifedipine in human plasma was sensitive and accurate, and could be used in nifedipine bioavailability and pharmacokinetic studies. 展开更多
关键词 Nifedipine sustained-release tablets LC-MS PHARMACOKINETICS BIOEQUIVALENCE
下载PDF
Preparation and <i>in Vitro</i>Drug Release Evaluation of Once-Daily Metformin Hydrochloride Sustained-Release Tablets 被引量:1
3
作者 Ling Zhao Yumeng Wei +4 位作者 Yong Mei Li Yang Yuan You Xufeng Yang Yanhong Jiang 《Pharmacology & Pharmacy》 2012年第4期468-473,共6页
The objective of this study was to develop once-daily metformin hydrochloride sustained-release tablets (MHSRT) and evaluate their in vitro release behavior. MHSRT were prepared by the film coating method. The in vitr... The objective of this study was to develop once-daily metformin hydrochloride sustained-release tablets (MHSRT) and evaluate their in vitro release behavior. MHSRT were prepared by the film coating method. The in vitro drug release rate of MHSRT and the commercial tablets Fortamet? made in the United States of America in water was fitted with zero order kinetic equation, and Ritger-Peppas kinetic equation in 0.1 M HCl and pH 6.8-phosphate buffer, respectively. The similarity factor f2 values of MHSRT in three different dissolution medium were 82, 80 and 74, respectively in comparison with imported Fortamet?, which were all greater than 50. The results of storage-stability showed that MHSRT were stable for at least 6 months under stress condition (40℃ ± 2℃, RH 75% ± 5%). Therefore, in this study, MHSRT were successfully prepared using optimized formulation technologies that meet mass produce. The in vitro release behavior of MHSRT was almost similar to that of imported Fortamet?. 展开更多
关键词 sustained-release tablets METFORMIN HYDROCHLORIDE In Vitro Release Rate Similarity Factor Kinetic Model
下载PDF
Preparation and evaluation of sustained-release azithromycin tablets in vitro and in vivo
4
作者 Le Sun Weixiang Zhang +1 位作者 Xiaohong Liu Jin Sun 《Asian Journal of Pharmaceutical Sciences》 SCIE CAS 2014年第3期155-161,共7页
The objective of this study was to prepare azithromycin(AZI)sustained-release products in order to allow for a high dose to be administered,reduce gastrointestinal side-effects and increase the compliance of patients.... The objective of this study was to prepare azithromycin(AZI)sustained-release products in order to allow for a high dose to be administered,reduce gastrointestinal side-effects and increase the compliance of patients.AZI sustained-release tablets with different release performance(F-I:T_(100%)=3 h and F-II:T_(100%)=8 h in pH 6.0 phosphate buffer)were successfully prepared by wet granulation.The in vitro release rate and drug release mechanism were studied.The release rate of F-Iwas affected by dissolutionmedia with different pH,but not for F-II.HixsoneCrowellmodel was the best regression fitting model for F-I and F-II.Additionally,F-I and F-II both belonged to non-Fick diffusion.Oral pharmacokinetics of the two tablets and one AZI dispersible tablet as reference were studied in six healthy beagle dogs after oral administration.Compared with the reference,the C_(max) of F-I and F-II were decreased,and the T_(max) were prolonged,in that case which meet the requirement of sustained-release tablets.The relative bioavailability of F-I and F-II were 79.12%and 64.09%.T-test ofAUC_(0-144),and AUC_(0-∞) for F-I and F-II indicated there was no significant difference between F-I and F-II.These mean that the extended release rate did not induce different pharmacokinetics in vivo. 展开更多
关键词 AZITHROMYCIN sustained-release tablet PHARMACOKINETICS UPLC-MS-MS
下载PDF
Clinical observation of Baitou Weng Decoction combined with mesalazine sustained-release tablets in treating heat-toxic and smoldering ulcerative colitis
5
作者 Qian-Zhang Ma Yun Li Yuan-Quan Ding 《Journal of Hainan Medical University》 2019年第12期37-42,共6页
Objective:To observe the clinical efficacy of Baitou Weng Decoction combined with mesalazine sustained-release tablets in the treatment of ulcerative colitis with febrile heat and its effect on immune function and ser... Objective:To observe the clinical efficacy of Baitou Weng Decoction combined with mesalazine sustained-release tablets in the treatment of ulcerative colitis with febrile heat and its effect on immune function and serum inflammatory factors.Methods: A total of 84 patients with ulcerative colitis were randomly divided into control group and treatment group, with 42 cases in each group. The control group was given mesalazine sustained-release tablets orally, while the treatment group was given Baitou Weng Decoction and mesalazine sustained-release tablets orally. The treatment period was 30 days and the patients were followed up for 3 months. After treatment, the clinical efficacy, quality of life, immune function and serum inflammatory factors of the two groups were observed.Results: The effective rate of treatment group (90.47%) was higher than that of control group (73.81%) (P<0.05);compared with before treatment, the scores of inflammatory bowel disease quality of life questionnaire scale in both groups were significantly improved (P<0.05), and the difference between the two groups was significant (P<0.05);after treatment, the plasma CD4+/CD8+ ratio and NK+ levels in both groups were significantly higher than those before treatment (P<0.05), and the treatment group was changed. The serum levels of tumor necrosis factor-α, interleukin-17 and interleukin-23 were significantly decreased in both groups after treatment (P<0.05), and the improvement was more significant in the treatment group (P<0.05). No significant adverse reactions were observed in the treatment group.Conclusions: Modified Baitou Weng Decoction combined with mesalazine in the treatment of heat-toxic and incandescent ulcerative colitis can significantly improve the clinical efficacy, improve the quality of life of patients, effectively regulate the expression level of serum inflammatory factors in ulcerative colitis patients, promote the recovery of patients' immune function, and have high drug safety. 展开更多
关键词 Baitou WENG DECOCTION MESALAZINE sustained-release tablets Hot toxicity ULCERATIVE colitis Immune function Serum inflammatory factor
下载PDF
Clinical observation on treatment of cancer pain with TCM oriented drugs combined with oxycodone sustained-release tablets and nimesulide sustained-release tablets
6
作者 Feng-Jiao He Ke-Xiong Li +2 位作者 Pu-Hua Zeng Hai-Yan Yi Xiao-Lan Jian 《TMR Cancer》 2018年第4期118-123,共6页
Objective: To study the effect of the transdermal preparation of traditional Chinese medicine in treating cancer pain. Methods: From October 2016 to January 2018, 126 patients with cancer pain were enrolled and divi... Objective: To study the effect of the transdermal preparation of traditional Chinese medicine in treating cancer pain. Methods: From October 2016 to January 2018, 126 patients with cancer pain were enrolled and divided into 4 groups, 39 patients in group A (directed TCM permeation), 26 patients in group B (oxycodone sustained-release tablets), 32 patients in group C (Chinese medicine directed drug penetration + oxycodone sustained-release tablets), and 29 patients group D (Chinese medicine directed drug penetration + oxycodone sustained-release tablets + nimesulide sustained release tablets), according to KPS scores. Results: Transdermal preparations of traditional Chinese medicine can significantly alleviate cancer pain. For the treatment of moderate to severe cancer pain, the Chinese medicine transdermal preparation can reduce the dosage of oxycodone sustained-release tablets. At the same time, the patient's KPS and NRS scores were significantly reduced. Moreover, the transdermal preparation of traditional Chinese medicine has a better therapeutic effect on visceral pain. Conclusion: The traditional Chinese medicine tra_nsdermal preparation combined with western medicine for the treatment of cancer pain may be a new method for the treatment of cancer pain. 展开更多
关键词 Chinese medicine directed drug Oxycodone sustained-release tablets Cancer pain Clinical efficacy
下载PDF
Pharmacokinetic Study on Lovastatin Sustained-release Tablet and Sustained-release Capsule in Begal Dogs
7
作者 付琳 代宗顺 +1 位作者 侯淑贤 万元胜 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2004年第2期116-119,共4页
This study pharmacokinetically examined the lovastatin sustained-release tablet and sustained-release capsule in Beagle dogs. An reversed-phase HPLC method was established for the determination of lovastatin in Beagl... This study pharmacokinetically examined the lovastatin sustained-release tablet and sustained-release capsule in Beagle dogs. An reversed-phase HPLC method was established for the determination of lovastatin in Beagle dog plasma. Pharmacokinetic findings were compared among three preparation(lovastatin sustained-release tablet,T p; sustained-release capsule,T J and conventional capsule). Our results showed that the pharmacokinetic parameters in 6 dogs after single-dose oral administration of three perparations were calculated. T max, C max and MRT revealed significant difference (P<0.05). Relative bioavailability was 111.5±16.9 % (T P) and 110.4%±9.6 % (T J). The pharmacokinetic parameters in the 6 dogs after multiple-dose oral administration of three perparations, T max, C max MRT and DF had significant difference (P<0.05); C av , C min and AUC 0-24 h displayed no significant difference (P>0.05). It is concluded that the lovastatin sustained-release tablet and sustained-release capsule are able to maintain a sustained-release for 24 h. 展开更多
关键词 LOVASTATIN sustained-release tablets sustained-release capsules PHARMACOKINETIC SINGLE-DOSE MULTIPLE-DOSE
下载PDF
Simultaneous Analysis of Indapamide and Related Impurities in Sustained-Release Tablets by a Single-Run HPLC-PDA Method
8
作者 YAO Wu ZHOU Shiwen CHENG Qiongru 《Wuhan University Journal of Natural Sciences》 CAS CSCD 2023年第4期333-340,共8页
The contents of indapamide and related impurities in generic indapamide sustained-release tablets were simultaneously detected by a single-run high performance liquid chromatography equipped with photodiode array dete... The contents of indapamide and related impurities in generic indapamide sustained-release tablets were simultaneously detected by a single-run high performance liquid chromatography equipped with photodiode array detector(HPLC-PDA)method for the quality control in this paper.The results showed the method had a good selectivity and was validated through linearity,limits of detection and quantification,recovery,and precision.The linear ranges of indapamide,2-methyl-1-nitroso-2,3-dihydro-1H-indole(impurity A,ImA),4-chloro-N-(2-methyl-1H-indol-1-yl)-3-sulphamoyl-benzamide(impurity B,ImB)and 4-chloro-3-sulfamoylbenzoic acid(impurity 1,Im1)were 0.028-1.80μg/mL(R=0.99995),0.060-1.20μg/mL(R=0.9996),0.0324-1.20μg/mL(R=0.99985)and 0.060-1.20μg/mL(R=0.9997)with detection limits of 0.0093,0.012,0.012 and 0.006μg/mL,respectively.ImA and Im1 were not detectable in the generic drug.The content of indapamide was 96.7%of the labeled amount with a relative standard deviation(RSD)of 1.30%,and the percentage of ImB relative to the labeled amounts of indapamide was 0.106%with an RSD of 1.82%.The content of other unspecified impurities all met the reference quality standards.The results provided references for the quality control and the quality standard study of generic indapamide sustained-release tablets. 展开更多
关键词 indapamide related impurity sustained-release tablets high performance liquid chromatography equipped with photodiode array detector(HPLC-PDA)
原文传递
Qualitative and quantitative analysis of HPLC fingerprint of Wuji gastric floating sustained-release tablets 被引量:1
9
作者 陈中芬 刘文 +2 位作者 陈大业 施晓伟 王群 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2015年第5期310-317,共8页
A qualitative and quantitative test method of fingerprint of Wuji gastric floating sustained-release tablets was established. High performance liquid chromatography (HPLC) was adopted, using Agilent ZORBAX SB-C18 co... A qualitative and quantitative test method of fingerprint of Wuji gastric floating sustained-release tablets was established. High performance liquid chromatography (HPLC) was adopted, using Agilent ZORBAX SB-C18 column (250 mm×4.6 mm, 5 μm) as the chromatographic column, and acetonitrile-0.05 mol/L potassium dihydrogen phosphate solution as the mobile phase in a gradient elution with the flow rate of 1.0 mL/min. Sample solution (10 μL) was injected and was tested at the wavelength of 225 nm for 75 min at the column temperature of 30 ℃, Fingerprint similarity software (2004A version) was used to conduct data analysis. A total of 11 batches of Wuji gastric floating sustained-release tablets were tested and analyzed with HPLC fingerprint. Seventeen common peaks were found and the similarity of the 11 batches of agents was greater than 0.9, indicating that the production process of the agent is stable and feasible. The method is operable and could effectively control the quality of Wuji gastric floating sustained-release tablets. 展开更多
关键词 FINGERPRINT HPLC Wuji gastric floating sustained-release tablets
原文传递
吲达帕胺结合氨氯地平片对高血压伴冠心病患者血压水平、心功能指标的影响
10
作者 李秀 王兰兰 马文涛 《中外医疗》 2024年第17期81-84,共4页
目的 研究吲达帕胺与氨氯地平片联合治疗高血压伴冠状动脉粥样硬化性心脏病(以下简称冠心病)患者在血压控制及心功能改善中的作用。方法 随机选取2022年1月—2023年10月山东省聊城市第三人民医院心内科收治的70例高血压伴冠心病患者为... 目的 研究吲达帕胺与氨氯地平片联合治疗高血压伴冠状动脉粥样硬化性心脏病(以下简称冠心病)患者在血压控制及心功能改善中的作用。方法 随机选取2022年1月—2023年10月山东省聊城市第三人民医院心内科收治的70例高血压伴冠心病患者为研究对象,按随机数表法分两组,各35例。对照组单用氨氯地平片,观察组联合使用氨氯地平片与吲达帕胺。比较两组血压控制水平及心功能改善效果。对比两组临床治疗效果及安全性。结果 观察组治疗总有效率高于对照组,差异有统计学意义(χ^(2)=4.200,P=0.040)。治疗后,观察组收缩压(121.51±9.98)mmHg、舒张压为(79.46±6.98)mmHg,低于对照组的(135.27±8.09)、(93.17±7.30)mmHg,差异有统计学意义(t=6.337、8.031,P均<0.001)。观察组左室射血分数、一氧化氮水平均高于对照组,左心室舒张末期内径、左心室收缩末期内径与内皮素-1水平均低于对照组,差异有统计学意义(P均<0.05)。两组不良反应发生率比较,差异无统计学意义(χ^(2)=0.000,P=1.000)。结论 吲达帕胺结合氨氯地平片能够促使高血压伴冠心病患者临床效果观察,实现良好的降压效果,从而减轻血管内皮功能损伤,促进心功能改善,安全有效。 展开更多
关键词 高血压 冠心病 氨氯地平片 吲达帕胺 血压水平 心功能指标
下载PDF
国产与进口吲达帕胺缓释片在健康人体的药代动力学及生物等效性 被引量:4
11
作者 徐平声 戴智勇 +4 位作者 李新中 秦群 马虹英 雷鹏 肖菁 《中国临床药理学杂志》 CAS CSCD 北大核心 2006年第3期184-187,共4页
目的评价国产和进口吲达帕胺缓释片(抗高血压药)在健康人体内的药代动力学与生物等效性。方法按自身对照随机交叉双周期试验设计, 20名健康志愿者单剂口服进口与国产吲达帕胺缓释片1.5 mg,用高效液相色谱-电化学检测法测定血浆中药物... 目的评价国产和进口吲达帕胺缓释片(抗高血压药)在健康人体内的药代动力学与生物等效性。方法按自身对照随机交叉双周期试验设计, 20名健康志愿者单剂口服进口与国产吲达帕胺缓释片1.5 mg,用高效液相色谱-电化学检测法测定血浆中药物浓度。结果药代动力学参数如下。单剂量:Cmax分别为(19.2±6.3)和(18.1±5.6)ng·mL-1;tmax分别为 (12.3±2.1)和(12.7±1.9)h;AUC0→72分别为(528.2±264.0)和(514.5 ±210.2)ng·h·mL-1;F为(100.7±16.3)%。多剂量:Cmax分别为(34.5 ±10.7)和(36.0±11.9)ng·mL-1;Cmin分别为(16.0±5.8)和(17.2± 6.0)ng·mL-1;tmax分别为(10.7±1.8)和(10.8±2.3)h;AUCss分别为 (568.8±198.2)和(584.7±195.5)ng·h·mL-1;F为(104.2±12.5)%。结论 2种吲达帕胺缓释片具有生物等效性。 展开更多
关键词 吲达帕胺缓释片 高效液相色谱-电化学检测法 药代动力学 生物等效性
下载PDF
吲达帕胺缓释片的制备及体外释放度测定 被引量:4
12
作者 谢清春 陈燕忠 +1 位作者 吕竹芬 何敏 《广东药学院学报》 CAS 2010年第6期561-563,共3页
目的制备吲达帕胺缓释片并测定其释放度。方法以进口市售片为对照片,以高效液相色谱法为测定释放度的方法,以释放度为指标筛选缓释片处方,考察填充剂类型(乳糖、可溶性淀粉及微晶纤维素)及羟丙基甲基纤维素(HPMC K4M)用量对释放度的影响... 目的制备吲达帕胺缓释片并测定其释放度。方法以进口市售片为对照片,以高效液相色谱法为测定释放度的方法,以释放度为指标筛选缓释片处方,考察填充剂类型(乳糖、可溶性淀粉及微晶纤维素)及羟丙基甲基纤维素(HPMC K4M)用量对释放度的影响;并对自制片和对照片的释放曲线进行相似性评价。结果以乳糖作填充剂,HPMC K4M的质量分数为25%时,自制缓释片的释放度与对照片比较差异无统计学意义。释放度测定方法:吲达帕胺的质量浓度在0.2~1.5μg.mL-1范围内与峰面积线性关系良好,低、中、高3个浓度的回收率分别是100.08%、99.67%、99.58%。结论自制缓释片处方工艺简单、经济,释放曲线与对照片相似。 展开更多
关键词 吲达帕胺 缓释片 高效液相色谱法 体外释放
下载PDF
吲达帕胺缓释片的研制及释药机理考察 被引量:6
13
作者 崔升淼 赵春顺 何仲贵 《中国医院药学杂志》 CAS CSCD 北大核心 2003年第7期397-399,共3页
目的 :研制吲达帕胺缓释片 ,并考察其释药机理。方法 :以HPMC为骨架材料 ,以微晶纤维素、乳糖和可压性淀粉调节释放度 ,对吲达帕胺缓释片的影响因素进行了考察 ,并采用正交试验设计筛选处方。结果 :吲达帕胺缓释片的组成为 :HPMCK4M 3 7... 目的 :研制吲达帕胺缓释片 ,并考察其释药机理。方法 :以HPMC为骨架材料 ,以微晶纤维素、乳糖和可压性淀粉调节释放度 ,对吲达帕胺缓释片的影响因素进行了考察 ,并采用正交试验设计筛选处方。结果 :吲达帕胺缓释片的组成为 :HPMCK4M 3 7.5mg,HPMCK15M 7.5mg,乳糖 45 .0mg,可压性淀粉 3 7.5mg,微晶纤维素 2 1.0mg,硬脂酸镁 1.5mg,药物的释放符合零级动力学方程 ,释放机制为骨架溶蚀机制 ;释药速率受介质 pH值的影响 ,几乎不受压片压力的影响。 结论 :研制的吲达帕胺缓释片体外释放符合国外同类产品的释药特性。 展开更多
关键词 吲达帕胺 羟丙基甲基纤维素 缓释片 释放度
下载PDF
国产与进口吲达帕胺片在中国健康人体的生物等效性 被引量:2
14
作者 于洋 杨汉煜 +2 位作者 胡玉钦 薛洪源 侯艳宁 《中国临床药理学杂志》 CAS CSCD 北大核心 2006年第6期432-435,共4页
目的研究国产和进口吲达帕胺片(抗高血压药)在中国健康人体的药代动力学,并评价2种制剂的生物等效性。方法用随机交叉试验,22名健康男性单剂量空腹口服国产和进口吲达帕胺片2.5mg,采集72h内动态血标本;用液相色谱-串联质谱法测定全血中... 目的研究国产和进口吲达帕胺片(抗高血压药)在中国健康人体的药代动力学,并评价2种制剂的生物等效性。方法用随机交叉试验,22名健康男性单剂量空腹口服国产和进口吲达帕胺片2.5mg,采集72h内动态血标本;用液相色谱-串联质谱法测定全血中吲达帕胺的浓度,计算药代动力学参数,并进行生物等效性评价。结果国产和进口片剂的tmax分别为(2.0±0.8)和(2.6±1.2)h,Cmax分别为(121.9±22.3)和(118.5±22.3)μg·L-1,AUC0-72h分别为(2464.9±423.2)和(2317.0±455.2)μg·h·L-1,t1/2分别为(15.4±1.9)和(15.2±2.1)h。国产制剂的相对生物利用度为(107.5±12.7)%。结论2种制剂具有生物等效性。 展开更多
关键词 吲达帕胺片 液相色谱-串联质谱法 生物等效性
下载PDF
高效液相色谱-串联质谱法测定人血浆中吲哒帕胺及其生物等效性研究 被引量:4
15
作者 佟玲 齐丹丹 +1 位作者 毕开顺 陈晓辉 《中国新药与临床杂志》 CAS CSCD 北大核心 2006年第11期851-855,共5页
目的:研究用高效液相色谱-串联质谱(HPLC-MS)法进行试验制剂吲哒帕胺片剂与参比制剂市售吲哒帕胺片剂生物等效性研究。方法:男性健康志愿者20名,随机分为2组,分别交叉单剂服用受试制剂或参比制剂吲哒帕胺片剂2.5 mg,采用HPLC-MS法,选... 目的:研究用高效液相色谱-串联质谱(HPLC-MS)法进行试验制剂吲哒帕胺片剂与参比制剂市售吲哒帕胺片剂生物等效性研究。方法:男性健康志愿者20名,随机分为2组,分别交叉单剂服用受试制剂或参比制剂吲哒帕胺片剂2.5 mg,采用HPLC-MS法,选择正离子检测的大气压化学电离源(APCI源),以甲醇-1%甲酸水溶液(75:25,V/V)为流动相,测定吲哒帕胺血药浓度,计算药动学参数,评价2制剂的生物等效性。结果:受试制剂和参比制剂主要药动学参数tmax为(1.4±s 0.4)和(1.4±0.4)h, Cmax为(30±6)和(30±5)μg·L-1,t1/2为(14.7±2.1)和(14.3±2.5)h,AUC0-72为(539±103)和(534±95)μg·h·L-1,AUC0-∞为(570±105)和(565±98)μg·h·L-1。受试制剂吲哒帕胺片剂相对生物利用度(F)为(102±13)%。结论:该方法选择性强、灵敏度高、操作简便,适用于吲哒帕胺制剂的生物等效性评价及临床药动学研究。 展开更多
关键词 吲哒帕胺 片剂 色谱法 高效液相 光谱法 质量 大气压化学电离 生物等效性
下载PDF
吲达帕胺片仿制药与原研药的溶出度一致性评价 被引量:3
16
作者 张翔 宋金春 陈莉 《中国药物警戒》 2016年第7期403-407,共5页
目的比较国内3种不同吲达帕胺片仿制药与原研药的体外溶出度,并将溶出曲线进行比较评价一致性。方法采用高效液相色谱法。色谱柱为Agilent TC-C18,流动相为甲醇-水-冰醋酸(55:45:0.1),流速1 m L·min-1,检测波长为240 nm,柱温为30℃... 目的比较国内3种不同吲达帕胺片仿制药与原研药的体外溶出度,并将溶出曲线进行比较评价一致性。方法采用高效液相色谱法。色谱柱为Agilent TC-C18,流动相为甲醇-水-冰醋酸(55:45:0.1),流速1 m L·min-1,检测波长为240 nm,柱温为30℃,进样量为20μL。采用桨法,溶出介质体积为900 m L,转速为50 rpm,分别以水、p H 1.2盐酸溶液、p H 4.0醋酸盐缓冲液、p H 6.8磷酸盐缓冲液为溶出介质测定溶出度,并通过计算相似因子(f2)评价二者溶出曲线的相似性。结果仅仿制药C与参比制剂D的溶出曲线基本相似,A和B与参比制剂溶出一致性差。结论部分国内仿制药与国外参比制剂溶出一致性较差,制备工艺有待改善。 展开更多
关键词 吲达帕胺 仿制药 原研药 溶出曲线
下载PDF
低剂量吲哒帕胺缓释片治疗原发性高血压的30小时动态血压评价 被引量:1
17
作者 黄高忠 顾兴建 +4 位作者 杜荣增 吴宗贵 王丽娟 陈琴珍 卢燕芳 《高血压杂志》 CSCD 2003年第6期546-548,共3页
目的 评价吲哒帕胺 1 5mg新型缓释片 (SRI .D)的长效降压疗效及安全性。方法  2 4例轻中度原发性高血压患者 ,服SRI .D 1 5mg前和 8周后分别进行连续 3 0小时的动态血压监测 ,并测定血钾及血尿酸 ,观察药物的安全性。结果 服药后诊... 目的 评价吲哒帕胺 1 5mg新型缓释片 (SRI .D)的长效降压疗效及安全性。方法  2 4例轻中度原发性高血压患者 ,服SRI .D 1 5mg前和 8周后分别进行连续 3 0小时的动态血压监测 ,并测定血钾及血尿酸 ,观察药物的安全性。结果 服药后诊所血压总有效率 54 2 %。SBP/DBP由治疗前的 (14 2 4± 11 9/ 97 2± 5 0 )mmHg降至治疗后的(13 2 5± 8 4/ 88 0± 6 0 )mmHg ,心率无明显改变。前 2 4小时ABPM血压由 (13 0 3± 9 1/ 86 3± 6 3 )mmHg降至 (12 3 4±10 3 / 81 4± 7 3 )mmHg ,延长段 6小时ABPM血压由 (13 6 9± 9 7/ 90 7± 6 0 )mmHg降至 (12 8 0± 8 6/ 85 7± 7 9)mmHg ,两者均有显著意义。SBP和DBP的T/P比值分别为 0 75和 0 73。治疗后血钾由 (4 6± 0 56)mmol/L下降至 (4 1±0 3 6)mmol/L(P <0 0 1) ,最低值为 3 5mmol/L(2例 )。血尿酸值由服药前的 (3 3 3 8± 73 0 )mol/L变为 (3 67 9± 88 3 )μmol/L ,异常的例数由 3例上升至 7例 ,但尚无统计学差异。 结论 吲哒帕胺 1 5mg缓释片每日 1次给药降压平稳而达 3 0小时以上 。 展开更多
关键词 吲哒帕胺 高血压 动态血压监测 动态血压监测 安全性 不良反应
下载PDF
培哚普利吲达帕胺片复方制剂治疗高盐饮食人群高血压的临床疗效观察 被引量:3
18
作者 丁立民 陈禹含 +2 位作者 李耕慧 王大伟 李冬冬 《齐齐哈尔医学院学报》 2017年第21期2500-2502,共3页
目的探讨培哚普利吲达帕胺片复方制剂对高盐饮食人群高血压的降压疗效。方法将齐齐哈尔市第一医院2016年3月至2017年3月收治的高盐饮食人群高血压患者96例,随机分为对照组和观察组各48例,对照组患者运用培哚普利(4mg)治疗,观察组患者运... 目的探讨培哚普利吲达帕胺片复方制剂对高盐饮食人群高血压的降压疗效。方法将齐齐哈尔市第一医院2016年3月至2017年3月收治的高盐饮食人群高血压患者96例,随机分为对照组和观察组各48例,对照组患者运用培哚普利(4mg)治疗,观察组患者运用培哚普利吲达帕胺片复方制剂(4mg/1.25 mg)治疗。结果治疗前,两组患者食盐摄入量、血清钠、血清钾、收缩压和舒张压比较,差异无统计学意义(P>0.05)。治疗后,两组患者收缩压和舒张压均显著下降,且观察组患者收缩压和舒张压降低程度更明显,差异有统计学意义(P<0.05),但两组患者治疗后食盐摄入量、血清钠、血清钾比较,差异无统计学意义(P>0.05)。观察组患者临床总有效率为91.67%,显著高于对照组患者临床总有效率68.75%,差异有统计学意义(Z=-3.048,P<0.05)。结论培哚普利吲达帕胺片复方制剂对高盐饮食人群高血压有显著的降压作用。 展开更多
关键词 高盐饮食人群高血压 培哚普利 培哚普利吲达帕胺片
下载PDF
吲达帕胺片溶出度检查方法研究 被引量:4
19
作者 赵喆 唐素芳 《中国药品标准》 CAS 2010年第4期271-274,共4页
目的:建立吲达帕胺片的溶出度检查方法。方法:照《中国药》典2005年版二部溶出度测定第一法,以磷酸盐缓冲溶液(pH6.8)900mL为溶出介质,转速为100r·min^-1,45min取样,用紫外一可见分光光度法测定溶出量,检测波长为240nm... 目的:建立吲达帕胺片的溶出度检查方法。方法:照《中国药》典2005年版二部溶出度测定第一法,以磷酸盐缓冲溶液(pH6.8)900mL为溶出介质,转速为100r·min^-1,45min取样,用紫外一可见分光光度法测定溶出量,检测波长为240nm。结果:吲达帕胺在0.141~3.373μg·mL^-1浓度范围内溶液浓度与吸光度线性关系良好(r=0.9997);平均回收率:糖衣片为99.1%(n=9,RSD为0.68%),薄膜衣片为99.5%(n=9,RSD为0.99%)。结论:本方法简便合理、准确可靠,可用于吲达帕胺片溶出度质量控制。 展开更多
关键词 吲达帕胺片 溶出度
下载PDF
吲哒帕胺单用或联用氯化钾控释片治疗老年原发性高血压临床观察 被引量:1
20
作者 马国添 文伟明 《广西医学》 CAS 2002年第8期1147-1149,共3页
目的 :探讨单用吲哒帕胺或吲哒帕胺联用氯化钾控释片对老年原发性高血压患者的疗效及副作用。方法 :60例老年原发性高血压患者随机分成 3组。对照组 2 0例 ,单用吲哒帕胺。治疗组 1用吲哒帕胺及氯化钾控释片 1.0 g/d,共 2 0例。治疗组 ... 目的 :探讨单用吲哒帕胺或吲哒帕胺联用氯化钾控释片对老年原发性高血压患者的疗效及副作用。方法 :60例老年原发性高血压患者随机分成 3组。对照组 2 0例 ,单用吲哒帕胺。治疗组 1用吲哒帕胺及氯化钾控释片 1.0 g/d,共 2 0例。治疗组 2用吲哒帕胺及氯化钾控释片 2 .0 g/d,共 2 0例。疗程均为 4周 ,观察治疗前后动态血压及血清钾水平。结果 :对照组及治疗组治疗后血压均有明显降低 (P <0 .0 5 ) ,但治疗组血压下降更明显 (P <0 .0 1) ,治疗组间血压下降无差异 (P >0 .0 5 )。对照组治疗后血钾较治疗前低 (P <0 .0 5 ) ,治疗组 1及治疗组 2治疗前后血钾无差异 (P >0 .0 5 )。治疗组 1药费低于治疗组 2。结论 :吲哒帕胺联用氯化钾控释片 1.0 g/d,降压效果好 ,副作用小 。 展开更多
关键词 吲哒帕胺 氯化钾控释片 治疗 原发性高血压 临床观察 老年人
下载PDF
上一页 1 2 4 下一页 到第
使用帮助 返回顶部